Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
Status:
Recruiting
Trial end date:
2026-04-20
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to
evaluate the safety of CD19 CAR-T therapy for patients with refractory myasthenia gravis, and
to evaluate the pharmacokinetics of CD19 CAR-T in patients.